Mycovia Pharmaceuticals

Mycovia Pharmaceuticals

Pharmaceuticals, 4721 Emperor BLVD, Durham, North Carolina, 27703, United States, 11-50 Employees

mycovia.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 91********

Who is MYCOVIA PHARMACEUTICALS

Mycovia Pharmaceuticals was formed in 2018 following the acquisition of Viamet Pharmaceuticals by NovaQuest Capital Management. At Mycovia, we are passionate about developing breakthrough...

Read More

map
  • 4721 Emperor BLVD, Durham, North Carolina, 27703, United States Headquarters: 4721 Emperor BLVD, Durham, North Carolina, 27703, United States
  • 2018 Date Founded: 2018
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $25 Million to $50 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 5122

checked-icon Does something look wrong? Fix it. | View contact records from MYCOVIA PHARMACEUTICALS

Mycovia Pharmaceuticals Org Chart and Mapping

Employees

Daniel Ullo

Regional Business Leader - Southeast

Susan McGaurn

Vice President Medical Affairs

Tami Wadsworth

Women’s Health Account Manager

Paul Dowler

Senior Director Clinical & Commercial Supply Chain

Nikki Curtis

Medical Science Liaison

Stephen Brand

Chief Development Officer

Jared Emerson

Senior Director of Commercial Insights & Analytics

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Mycovia Pharmaceuticals

Answer: Mycovia Pharmaceuticals's headquarters are located at 4721 Emperor BLVD, Durham, North Carolina, 27703, United States

Answer: Mycovia Pharmaceuticals's phone number is 91********

Answer: Mycovia Pharmaceuticals's official website is https://mycovia.com

Answer: Mycovia Pharmaceuticals's revenue is $25 Million to $50 Million

Answer: Mycovia Pharmaceuticals's SIC: 5122

Answer: Mycovia Pharmaceuticals has 11-50 employees

Answer: Mycovia Pharmaceuticals is in Pharmaceuticals

Answer: Mycovia Pharmaceuticals contact info: Phone number: 91******** Website: https://mycovia.com

Answer: Mycovia Pharmaceuticals was formed in 2018 following the acquisition of Viamet Pharmaceuticals by NovaQuest Capital Management. At Mycovia, we are passionate about developing breakthrough therapies in womens health and dermatology. Our lead product candidate, VT-1161, is being developed as a treatment for recurrent vulvovaginal candidiasis (RVVC), a yeast infection that affects millions of women each year and often leads to distressing physical discomfort and a negative impact on psychological well-being. In studies to date, VT-1161 has demonstrated a high degree of potency against the organisms that cause RVVC. It may also have a lesser tendency to induce drug resistance and the variety of side effects that limit the use of currently available oral antifungal therapies. We are conducting global Phase 3 clinical trials in RVVC. VT-1161 has also been studied in onychomycosis, a fungal infection of the nail which affects approximately 35 million people in the United States and millions more around the globe. Onychomycosis can be a significant medical issue particularly for diabetics or other patients with compromised immune systems or poor circulation of the lower extremities.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access